Analysts Unconvinced By Sanofi Best-In-Class Claims For Sarclisa
Much Ground To Make Up On J&J's Darzalex
Sanofi presented new data at a post-ASCO briefing to back its claim that Sarclisa can become the anti-CD38 of choice for the treatment of multiple myeloma ahead of Darzalex. The investment community is not so sure.
